2019 Keynote Speakers

Tuesday, 17 September

7:30 - 17:00 Registration Open

7:30 - 8:35 Morning Coffee

SHARED OPENING PLENARY KEYNOTE: EVALUATING NEW TECH, CONNECTING DIRECTLY WITH PATIENTS, AND UNDERSTANDING DATA OWNERSHIP

8:35 Organizer's Welcome

Micah Lieberman, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)

8:40 Chairperson's Opening Remarks: Novel Tech and Data - First and Foremost: Think about the Patient

Bert Hartog, PhD, Senior Director, Clinical Innovation, Janssen Pharmaceutica N.V.

The pace of new technology becoming available is dizzying. How does one minimise risk to trials and select what tech to use and when a supplier is ready for use at scale? What is the impact of using tech on patients’ experience participating in a trial, is friction-less tech becoming reality? Tech generates new data, patients have the right to own their data, but where does this leave other stakeholders’ interests? Does Pascal’s principle from physics apply and can a new equilibrium be established?

8:50 Customer-Focused Research and Healthcare: A New Breed of Digital Health Tools to Deploy in Tomorrow’s Trials

Koen Kas, MD, Founder & CEO, Healthskouts; Partner, HealthStartup.eu

This talk will introduce Real World Data you’ve never considered of value or that you didn’t trust. Emerging digital health tools enable accessing and capturing these data for the first time ever. How can you use them to spice up your clinical trial design in order to obtain unique selling points for emerging drugs? What are ways to really move into Personalised Medicine and get financially rewarded for it? Welcome to a fresh look into clinical trial design and execution with concrete examples of a “TripAdvisor” toolbox to apply immediately.

9:20 INTERACTIVE PANEL DISCUSSION: Patient Data Ownership and Privacy in Clinical Research Today

 

Comis LarissaModerator: Larissa Comis, Product Lead, Shared Investigator Platform, Life Sciences Products & Platforms, Cognizant


Panelists:

Bert Hartog, PhD, Senior Director, Clinical Innovation, Janssen Pharmaceutica N.V.


Koen Kas, MD, Founder & CEO, Healthskouts; Partner, HealthStartup.eu


Greg Hersch, PhD, Head, Innovation, Global Development Operation, Novartis


Pharmaceutical companies are increasingly focused on a direct connection with patients at scale. With the advent of GDPR as well as broad concerns around privacy and data ownership globally, having the voice of the patient is a central theme. Control of the data and ongoing usage of the data becomes an important topic of discussion as companies focus on a more targeted and direct involvement with patients. Topics to be discussed:

  • Who owns the patient data in clinical research?
  • Do the patients get longitudinal choice and control of ongoing use of their data?
  • What are the opportunities in a consented life-long relationship with patients, via a digital twin?

10:00 Grand Opening Coffee Break with Exhibit Viewing

Wednesday, 18 September

CLINICAL RESEARCH NEWS EUROPEAN INNOVATIONS AWARDS & SHARED CLOSING PLENARY KEYNOTE: OPERATIONALISING DIGITAL TECH, PATIENT-CENTRIC AND VIRTUAL TRIALS

14:10 Clinical Research News European Innovations Awards

Allison Proffitt, Editorial Director, Bio-IT World & Clinical Research News

The Clinical Research News European Innovation Awards recognizes outstanding examples of applied strategic innovation—partnerships, deployments, and collaborations—that manifestly improve the clinical trial process. Clinical Research News is seeking submissions to its European Innovations Awards:
www.clinicalinformaticsnews.com/BestPracticeAwards/


14:15 Chairperson’s Remarks

Denis McMillan, Vice President, Solutions Consulting – CROps, Strategic Feasibility, Parexel



14:20 Achieving Next-Gen Consumer Health and Research through Patient Engagement and Digital Tech

Raj Pallapothu, mHealth Global Business Lead, Bayer Pharmaceuticals; mHealth Global Advocate


By facilitating patient recruitment, consent, engagement and involvement in the clinical research process, mHealth technology is disrupting consumer health and clinical trials simultaneously. This presentation will cover 1. Emergence of wearables, sensors, bio-markets in clinical trials, 2. Patient adaptation, challenges at site level, 3. Data transfers, privacy, portability growing need and associated challenges, 4. Operational challenges, 5. Value proposition, and 6. Market trends.

Feys_Caroline14:50 Virtual Trials: Overcoming the Barriers to Patient Centricity

Caroline Feys, MSc, MBA, Associate Director, Janssen Clinical Innovation

Virtual or site-less trials has become a new buzz-word. Based on the state-of-the-art, we will explore the components of virtual trials that are new and components which have been used for a while but are now embedded in the virtual trial business architecture. Besides highlighting the opportunities and the challenges, we will emphasize the benefits for the different stakeholders in the health ecosystem, based on concrete and already accomplished examples. The two presentation anchor points are how virtual trials can improve patient centricity and the role of real-world data. Given that we continue facing challenges with recruitment, enrollment, site activation, patient retention, etc., discussions around novel trial conduct are essential.

15:20 Closing Remarks

Micah Lieberman, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)